List view / Grid view
9 March 2016 | By GlobalData
The UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves...
24 February 2016 | By Victoria White
The osteoarthritis treatment market will experience seismic changes over the next decade, according to a GlobalData analyst...
24 February 2016 | By Victoria White
GlobalData says China will continue to dominate the hepatitis B treatment space, as its market share rises from 38.8% in 2014 to 47.2% by 2024...
15 February 2016 | By Victoria White
A GlobalData analyst says that the combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake...
12 February 2016 | By Victoria White
The recent FDA approval of Adzenys will provide patients who have problems swallowing pills with easy-to-administer drug options, according to GlobalData analyst...
9 February 2016 | By Victoria White
An analyst from GlobalData says promising clinical trial data for Gilotrif (afatinib) will strengthen the drug’s position in NSCLC treatment markets outside the US...
3 February 2016 | By Victoria White
GlobalData says the treatment market for head and neck cancer will expand almost fourfold from $386 million in 2014 to $1.53 billion...
2 February 2016 | By GlobalData
A GlobalData analyst says increased collaboration and further financial incentives are required to fight the mounting threat posed by superbugs...
28 January 2016 | By Victoria White
GlobalData states that the limited growth in the B-cell NHL treatment market will be hindered by the entry of biosimilars and generics combined with a weak pipeline...
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
22 January 2016 | By Victoria White
GlobalData states that the impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents...
21 January 2016 | By Victoria White
The pulmonary arterial hypertension treatment market will grow from $3.45 billion in 2014 to $4.75 billion by 2024, according to research and consulting firm GlobalData...
20 January 2016 | By Victoria White
GlobalData says the expansion will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease...
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
